TX-TXONE-NETWORKS
TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, published its 2023 annual report detailing a growing range of cybersecurity issues facing global industries. The Crisis of Convergence: OT/ICS Cybersecurity 2023, which is publicly available for free download, details diverse intensifying challenges, including growth in attacks via Ransomware-as-a-Service (RaaS) models, exploitation of supply-chain vulnerabilities and prevalence of state-sponsored hackers and other politically motivated actors in the wake of geopolitical issues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130429836/en/
(Graphic: Business Wire)
TXOne Networks in September 2023 surveyed 405 key IT and OT security decision-makers from across multiple global markets and sectors including automotive, pharmaceuticals and biotechnology, chemical, general manufacturing, oil, and gas and transportation. The Crisis of Convergence: OT/ICS Cybersecurity 2023 distills the survey findings, alongside extensive TXOne Networks threat research from 545 cybersecurity incidents around the world in 2023.
“The threat landscape has intensified significantly in the industrial manufacturing and critical infrastructure sectors, leading to destructive events, economic losses, and potential risks to human safety...,” reads the TXOne Networks report, which was produced in collaboration with Frost & Sullivan. “Organizations emphasize the protection of critical OT (Operational Technology) assets as a top priority, with data security being a key investment area within their OT security budget allocations. ... Organizations are also seeking to invest in strengthening the resilience of their technological infrastructure and are turning to innovative approaches like Cyber-Physical Systems Detection and Response (CPSDR), which integrates OT expertise across various domains. This enhances OT security posture and resilience against evolving threats, enabling organizations to better protect their operations and ensure resilience in the face of a constantly changing threat environment.”
The Crisis of Convergence: OT/ICS Cybersecurity 2023 explores a range of topics relevant to contemporary OT/ICS cybersecurity:
- Ransomware threats
- OT system maintenance and Information Technology (IT) integration concerns
- Nation-state cyberattacks and implications
- Dedicated teams for OT and Industrial Control System (ICS) security management
- OT/ICS cybersecurity investment
- New regulations and standards propelling OT/ICS defense
- Supply-chain Integrity
“The Crisis of Convergence: OT/ICS Cybersecurity 2023 is the result of a thorough research and technical analysis that is aimed at delivering up-to-date insights into the global threat landscape and the tactics that malicious actors employ to launch attacks,” said Terence Liu, chief executive officer (CEO) of TXOne Networks. “The findings are clear. Organizations must move well beyond regulatory compliance in their OT/ICS cybersecurity strategies if they are to successfully adapt for the constantly evolving threat. Safeguarding the availability, reliability and security of revenue-generating operations will depend on new governance structures, enhanced team and technical capabilities, integration of advanced threat detection and response into cybersecurity frameworks and risk management across the supply chain.”
Download TXOne Networks’ The Crisis of Convergence: OT/ICS Cybersecurity 2023.
About TXOne Networks
TXOne Networks offers cybersecurity solutions that ensure the reliability and safety of industrial control systems and operational technology environments. TXOne Networks works together with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense. TXOne Networks offers both network-based and endpoint-based products to secure the OT network and mission-critical devices using a real-time, defense-in-depth approach. www.txone.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130429836/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
